Clinical trials: Flu Vaccine
Hemodialysis Patients
The Immunogenicity of Intradermal Influenza Vaccination in Hemodialysis Patients
The purpose of this study is to determine whether half-dose intradermal influenza vaccine is as immunogenic as standard dose intramuscular vaccine in hemodialysis patients.
- Trial name
- NCT01273974
- Testing
- intradermal influenza vaccine, intramuscular influenza vaccine
- Where
- Iran
- Volunteers
- 130 people
- Sponsor
- Shiraz University of Medical Sciences
Influenza
A Trial to Test the Response to Different Vaccination Regimens With an H5N1 Vaccine With AS03 in Adults Aged 18-64
The purpose of the study is to characterize the immunogenicity \& safety of 2 doses of GSK's avian flu vaccine GSK 1557484A given according to different regimens to adults aged 18 to 64 years
- Trial name
- NCT00695669
- Testing
- Influenza A (H5N1) Virus Monovalent Vaccine
- Where
- 3 sites in Canada
- Volunteers
- 312 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Influenza, Human
Enhanced Safety Surveillance of GlaxoSmithKline's (GSK's) Quadrivalent Seasonal Influenza Vaccines During the 2018/19 Influenza Season
The purpose of this study is to comply with the European Medicines Agency (EMA) guidance on enhanced safety surveillance for seasonal influenza vaccines in the European Union (EU) and aims to assess adverse events of interest…
- Trial name
- NCT03688620
- Testing
- Passive enhanced safety surveillance
- Where
- 9 sites in Belgium, Germany and 1 more
- Volunteers
- 1,060 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Influenza, Human
A Study to Evaluate the Immune Response and Safety of a Vaccine Against Influenza in Adults 18-64 Years of Age
This clinical trial will study an investigational seasonal influenza vaccine in adults 18 to 64 years of age. The vaccine is based on messenger ribonucleic acid, also called mRNA.
- Trial name
- NCT07851246
- Testing
- mRNA Seasonal Flu vaccine, Comparator 1, Comparator 2
- Where
- 12 sites in United States
- Volunteers
- 3,000 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Influenza and Pneumonia
Study on Combined Vaccination With Quadrivalent Influenza Vaccine and 23-valent Pneumococcal Polysaccharide Vaccine
This study is an open-label,single center phase Ⅳ clinical trial of combined immunization with quadrivalent influenza vaccine and 23-valent pneumococcal polysaccharide vaccine.The purpose of this study is to evaluate the safety…
- Trial name
- NCT05471531
- Testing
- Combined vaccination with quadrivalent influenza vaccine and 23-valent pneumococcal polysaccharide vaccine, Separate vaccination with quadrivalent influenza vaccine and 23-valent pneumococcal polysaccharide vaccine
- Where
- 4 sites in China
- Volunteers
- 3,000 people, healthy volunteers welcome
- Sponsor
- Sinovac Biotech Co., Ltd
Healthy Subjects
Immunogenicity and Safety of Two Adjuvant Formulations of an Egg-Derived Pandemic Vaccine
Several combinations of H5N1 antigen concentrations and aluminium-hydroxide adjuvant concentrations will be tested for their safety and capacity to induce a specific immune response.
- Trial name
- NCT00562237
- Testing
- S205 10ugHA, S205 30ugHA, S205 10ugHA+500ugAlOH
- Where
- 6 sites in Finland, Germany
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- Solvay Pharmaceuticals
Influenza
Safety, and Immunogenicity of Two Influenza Vaccines in Healthy Subjects 3 to 64 Years Old
This protocol is designed to evaluate safety, clinical tolerability and immunogenicity of the 2007 southern hemisphere formulation of a Novartis conventional influenza vaccine licensed in the EU and many other worldwide…
- Trial name
- NCT00464672
- Testing
- Influenza virus vaccine, Comparator influenza vaccine
- Where
- 2 sites in Argentina
- Volunteers
- 1,893 people, healthy volunteers welcome
- Sponsor
- Novartis
Influenza, Human
Evaluate Safety of GCFLU® Administered Intramuscularly in Healthy Vietnamese Volunteer Aged From 3 Years Old
An open label, non-comparative bridging study to evaluate the safety of GCFLU® (seasonal influenza vaccine) administered intramuscularly in healthy Vietnamese volunteer aged from 3 years old
- Trial name
- NCT02723812
- Testing
- GCFLU® Influenza vaccine (Split virion, Inactivated)
- Where
- Vietnam
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Institute of Clinical Research and Clinical Trial Support for Vaccine and Biological Products
Pregnancy Related, Influenza Virus Vaccine Adverse Reaction
Maternal and Fetal Outcomes Following Influenza Vaccination in Pregnancy
This is a nationwide cohort study to assess maternal and fetal outcomes following vaccination with a quadrivalent influenza vaccine (QIV) during pregnancy.
- Trial name
- NCT04579822
- Testing
- influenza vaccine
- Volunteers
- 300,000 people, healthy volunteers welcome
- Sponsor
- Sungkyunkwan University
Influenza, Respiratory Tract Infections
Patient Portal Flu Vaccine Reminders (5)
This trial is taking place in Los Angeles, CA at clinics within the UCLA Health System. The study design is a 2x2 nested factorial design.
- Trial name
- NCT05525494
- Testing
- Text Fixed R/R Messages with Direct Appointment Schedule Link, Text Pre-Appointment Reminder, Portal Pre-Commitment Prompt with Tailored R/R Messages with Direct Appointment Schedule Link
- Where
- United States
- Volunteers
- 262,085 people
- Sponsor
- University of California, Los Angeles
Reminder System for Influenza Vaccines
Centralized IIS-based Reminder/Recall to Increase Childhood Influenza Vaccination Rates in New York State
Despite U.S. guidelines for influenza vaccination of all children starting at age 6 months, only about half of children are vaccinated annually, leading to substantial influenza disease in children and spread of disease to…
- Trial name
- NCT02924467
- Testing
- 1 Notice, 2 Notices, 3 Notices
- Volunteers
- 100,000 people
- Sponsor
- University of California, Los Angeles
Influenza, Human
A Study To Learn About The Study Vaccine (Called Self-Amplifying Ribonucleic Acid (RNA)) For The Prevention of Influenza
The purpose of this clinical trial is to learn about the safety and effects of the study vaccine for the potential prevention of influenza. The study vaccine is called Self-Amplifying Ribonucleic Acid vaccine (saRNA vaccine).
- Trial name
- NCT05227001
- Testing
- PF-07852352 Influenza saRNA 1, PF-07836391 Influenza saRNA, PF-07836394 Influenza saRNA
- Where
- 24 sites in United States
- Volunteers
- 440 people, healthy volunteers welcome
- Sponsor
- Pfizer
Influenza
Comparison of Safety, Tolerability and Immunogenicity of Influenza Vaccines in Adults and Elderly
The purpose of the study is to evaluate safety, tolerability and immunogenicity (in a subset) following a dose of a trivalent subunit influenza vaccine produced either in mammalian cells or in embryonated hen eggs, in healthy…
- Trial name
- NCT00306527
- Testing
- Cell culture derived influenza vaccine, egg-derived influenza subunit vaccine
- Where
- 5 sites in Poland
- Volunteers
- 2,235 people, healthy volunteers welcome
- Sponsor
- Novartis Vaccines
Influenza Immunisation, Healthy Volunteers
Study of Recombinant Influenza Vaccine Containing Different H3 Antigens Without or With Adjuvant in Healthy Adult Subjects
The primary objectives of the study are: To describe the safety profile of the different formulations in all participants To describe the hemagglutinin inhibition (HAI) and seroneutralization (SN) antibody responses against…
- Trial name
- FBP00004 (NCT04451954)
- Testing
- Quadrivalent RIV with H3 strain 1, Quadrivalent RIV with H3 strain 1 and adjuvant, Quadrivalent RIV with H3 strain 2
- Where
- 5 sites in United States
- Volunteers
- 210 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Influenza (Pandemic)
Safety Study of an Influenza Vaccine Against a Potential Pandemic Strain of Flu
The purpose of this study is to evaluate how well the vaccine is tolerated at sites where administrations are given, any effects it may have on subjects' wellbeing and whether it can produce antibody responses in the body that…
- Trial name
- NCT00347529
- Testing
- pPML7789 with and without pPJV2012 administered by PMED
- Where
- United Kingdom
- Volunteers
- 75 people, healthy volunteers welcome
- Sponsor
- PowderMed
Influenza Immunization (Healthy Volunteers)
Safety Surveillance of VaxigripTetra® and Efluelda® Influenza Vaccines in Europe During the Influenza Season 2023/24
This EPSS will determine the vaccinee reporting rates (RRs) of suspected ADRs following routine vaccination with VaxigripTetra® and Efluelda® respectively, during the NH influenza season 2023/24.
- Trial name
- NCT06059456
- Testing
- Quadrivalent Influenza Vaccine, High-Dose Quadrivalent Influenza Vaccine
- Where
- 11 sites in Finland, Germany
- Volunteers
- 2,078 people, healthy volunteers welcome
- Sponsor
- Sanofi
Influenza, Infectious Disease
Brief Influenza Vaccine Education to Pregnant Women
The investigators will conduct a brief educational intervention to pregnant women who have not yet received the influenza vaccine in this pregnancy to improve the uptake of seasonal influenza vaccine.
- Conditions
- Influenza, Infectious Disease, Pregnancy
- Trial name
- NCT01772901
- Testing
- Influenza Vaccine Intervention
- Where
- 4 sites in Hong Kong
- Volunteers
- 321 people, healthy volunteers welcome
- Sponsor
- The University of Hong Kong
Impact of Vaccination
Intranasal LAIV Mucosal Immunity Examination
The research of the investigators is focused on the understanding how the immune system functions and responds to intranasal vaccines.
- Trial name
- NCT07093281
- Testing
- Live Attenuated Influenza Vaccine
- Where
- United States
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- University of Maryland, Baltimore
Influenza
Effectiveness of SMS Nudging to Increase Coverage of Influenza Vaccination Among the Elderly
The trial will investigate to what extent SMS reminders for influenza vaccination increases coverage of influenza vaccination among elderly from the majority population, and among elderly from immigrant groups with low…
- Trial name
- InfluSMS (NCT06486766)
- Testing
- Norwegian SMS, Polish/Ukrainian SMS
- Volunteers
- 1,000,000 people
- Sponsor
- Norwegian Institute of Public Health
Reminder Systems, Influenza Vaccines
Centralized IIS-based Reminder/Recall to Increase Childhood Influenza Vaccination Rates
Despite U.S. guidelines for influenza vaccination of all children starting at age 6 months, only about half of children are vaccinated annually leading to substantial influenza disease in children and spread of disease to adults.
- Trial name
- NCT02761551
- Testing
- Reminder notifications via autodialer
- Volunteers
- 56,549 people
- Sponsor
- University of Colorado, Denver